A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Phase 2 Completed 75 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Timeline

Start: 2023-08-23
Primary completion: 2024-01-16
Completion: 2024-04-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQC3721	Unknown	—	Inhaled
Background	Salbutamol	Unknown	—	Inhaled

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Summary

Timeline

Drugs

Indications